An iPro®2 professional continuous glucose monitoring (CGM) evaluation will record your glucose levels and will give your healthcare provider insights into how your diet, medication, and daily activities really affect your glucose levels.
iPro®2 professional CGM evaluation is a small, lightweight and watertight continuous glucose monitoring (CGM) device that takes a glucose reading every five minutes.
Wear it for a few days for a more complete picture of your glucose levels.
J.D. was put on an iPro®2 professional CGM evaluation to evaluate his glucose variability. Based on the results of his evaluation his doctor prescribed a long-acting insulin.
J.D. had always been told he had pre-diabetes. “As a busy police officer,” he said, “it’s just easier to eat fast food. I don’t know when the next meal will be.”
Once he and his doctor reviewed his iPro®2 professional CGM evaluation, J.D. quickly saw how high his sensor glucose really was and he decided to make some changes.
About three months later his doctor put him on iPro®2 professional CGM evaluation for a follow-up evaluation.
Since J.D. had cut back on second servings and pretty much stopped eating fast food, they saw a real improvement in his glucose variability.
His doctor was able to discontinue his insulin and J.D. no longer takes oral medications for his diabetes.
Get a more complete picture
An iPro®2 professional CGM evaluation helps you learn what works for you so that you can better control your diabetes.
Gain insights into spending more time within range
Therapy adjustments made with CGM data have been proven to:
Introducing the iPro®2 professional CGM evaluation myLog app — an easy and convenient way of logging daily activity while on your iPro2 professional CGM evaluation.
Medtronic and Fitbit recently announced a partnership to integrate health and activity tracking with the iPro2 Professional CGM system. The iPro2 myLog mobile app is the first data integration effort resulting from this partnership.
To learn more click here.
1.Kaufman FR, Gibson LC, Halvorson M, et al. A pilot study of the continuous glucose monitoring system. Diabetes Care. 2001;24(12):2030-2034.
2. Battelino T, Conget I, Olsen B, et al; and SWITCH Study Group. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomized controlled trial. Diabetologia. 2012:55:3155-3162.
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med. 1993;329(14):977-986.
4. Bergenstal RM, Tamborlande WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363(4):311-320.
Fitbit is a registered trademark and service mark for Fitbit, Inc. iPro2 myLog is designed for use with the Fitbit platform. This product is not put out by Fitbit, and Fitbit does not service or warrant the functionality of this product.
Android is a trademark of Google Inc. iPro2 and CareLink are registered trademarks of Medtronic MiniMed Inc.